Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Adamis Pharmaceuticals (ADMP): Third Time Is The Charm

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) shares gained more than 50% today following the approval of its pre-filled single dose syringe for the emergency treatment of allergic reactions.

Last week I sent the following email to our readers:

I usually don’t guarantee returns because investing is unpredictable. However, occasionally, I come across ideas that are near slam dunk cases. The risk-return combination of these ideas are so attractive that I don’t have much to lose by offering return guarantees. We came across two of these ideas last year.

In May 2016, I offered a 10% return guarantee within a month and my stock pick delivered that return within a week. In August 2016 I offered a 20% return guarantee within a year and my second stock pick delivered that return within 4 weeks.

Today, I will share a stock pick that I believe will gain at least 20% within two weeks. If this stock fails to return 20% by the end of June 20th, I will refund 100% of your subscription fee to our premium monthly activist newsletter.

These opportunities don’t come along very often and this is a short-term opportunity that you need to act very quickly to take advantage of.”

Sio Capital

I was talking about Adamis Pharmaceuticals Corporation (ADMP) in that email. We have been recommending this stock for almost three years in anticipation of this approval (Sio Capital’s Michael Castor recommended the idea). Last year ADMP came close, its stock price peaked above $10 prior to FDA’s decision, but received a CRL from the FDA instead. Its stock price cratered following this delay. One negative side effect of this delay is that ADMP had to raise capital multiple times and dilute the existing shareholders. As a result of these actions its current stock price isn’t likely to reach last year’s peak in the next couple of days.

I will be taking a closer look at Adamis Pharmaceuticals over next day or two and publish my opinion in the upcoming issue of our monthly newsletter. If you are a patient investor and looking for stocks that will go up 500% within 2-3 years, I actually have another fantastic stock pick that trades at an extremely attractive price. I will also share this idea in the upcoming issue of our monthly newsletter this weekend.